BDNF and Parkinson disease: However, there is no consensus about the neuroprotective functions of fingolimod, as Koming et al. reported there was no neuroprotection after fingolimod pretreatment in an MPTP model of Parkinson’s disease, nor was there any sustainable BDNF enhancement (Komnig et al., 2018).